HER-2 overexpression

Recent advances in molecular profiling and the development of HER2-directed ADCs have fundamentally reshaped the therapeutic relevance of HER2 in UC, enabling activity even in tumors with heterogeneous or low expression of HER2. This comprehensive narrative review synthesizes current knowledge on HER2 biology in UC, addresses challenges in biomarker assessment, critically appraises the evolving clinical trial landscape of HER2-directed ADCs, explores the interaction between HER2 and other oncogenic alterations and discusses mechanisms of resistance with future directions for HER2-targeted strategies in UC.

P=N/A, N=35, Completed, Semmelweis University

Combined with trastuzumab's targeting, this leads to marked suppression of HER2-positive BT474 xenograft tumors in mice. Our design may offer a powerful and universal modality for precise diagnosis and treatment of HER2-positive malignant tumors.

She completed adjuvant chemotherapy, radiotherapy, and HER2-targeted therapy, with no recurrence at 2-y follow-up. This case emphasizes deliberate review of the complete hybrid SPECT/CT field of view during parathyroid imaging.

HER2 overexpression appears to be associated with poorer outcomes in advanced and resectable gastric cancer. Standardizing diagnostic criteria and integrating HER2 assessment into multimarker panels could enhance prognostic accuracy and guide personalized therapeutic decisions.

This case illustrates successful management of HER2-positive brain metastases from cervical cancer using a multimodal approach combining surgery, radiotherapy, and systemic therapy with pyrotinib and capecitabine. The durable complete response with manageable toxicity underscores the therapeutic potential of HER2-targeted therapy as part of a multimodal regimen; however, further studies are required to validate these findings and optimize personalized treatment strategies.

This guidebook reviews the current guidelines for HER2 testing and reporting in carcinomas of different organ systems. In addition, it discusses the challenges of designing a unified biomarker reporting format to cover alternative scoring systems.

P1, N=28, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Aug 2026

HER2-low status was associated with worse OS in breast cancer patients with certain negative prognostic factors compared with HER2-zero status. Additionally, HER2-low1+ and HER2-low2+/ISH(-) subgroups predominantly exhibited HR+ status.

This study establishes a fully automated CT-based deep learning pipeline for HER2 status prediction in unresectable GBC. Validation in larger, multi-institutional cohorts is warranted.

The molecular subtypes of breast cancer exhibited distinct multimodal ultrasonographic characteristics. Multimodal ultrasonography showed potential value for noninvasive prediction of breast cancer molecular subtypes and may provide auxiliary information for individualized therapeutic decision-making.

P2, N=63, Completed, City of Hope Medical Center | Active, not recruiting --> Completed